Alkermes presenting new research related to ALKS 2680 at SLEEP 2025

Alkermes (ALKS) plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies June 8-11 in Seattle. ALKS 2680 is the company’s novel, investigational, oral orexin 2 receptor, or OX2R, agonist in phase 2 development as a once-daily treatment for narcolepsy type 1 – NT1 -, narcolepsy type 2 – NT2 – and idiopathic hypersomnia – IH -. Seven abstracts were accepted for poster presentation. The one abstract selected for dual presentation describes quantitative electroencephalography exploratory results from the phase 1b study of ALKS 2680 in patients with NT1, NT2 and IH. Findings demonstrated a statistically significant, wake-associated qEEG profile with ALKS 2680 compared to placebo. In addition, in an oral presentation, Alkermes’ VP of Clinical Development, will provide an overview of the ALKS 2680 development program and Alkermes’ broader orexin portfolio. Additional presentation highlights include: pooled data from the phase 1b study which showed that single doses of ALKS 2680 were generally well tolerated and led to statistically significant, clinically meaningful improvements in mean sleep latency at all doses tested in patients with NT1, NT2 or IH; results from a cardiac safety analysis in healthy volunteers, which demonstrated a lack of any effects of ALKS 2680 on QTc prolongation, heart rate or cardiac conduction; study design and methods for Vibrance-3, a recently initiated phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with IH; findings from a retrospective, cross-sectional analysis of the 2021/2023 U.S. National Health and Wellness Survey evaluating the clinical, economic and humanistic burden of narcolepsy.